BeOne Medicines Ltd
267 hedge funds and large institutions have $11.6B invested in BeOne Medicines Ltd in 2025 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 83 increasing their positions, 79 reducing their positions, and 25 closing their positions.
168% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 25
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
44% more capital invested
Capital invested by funds: $8.07B → $11.6B (+$3.51B)
17% more funds holding
Funds holding: 228 → 267 (+39)
5% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 79
3% more call options, than puts
Call options by funds: $44.1M | Put options by funds: $42.9M
0.18% less ownership
Funds ownership: 3.5% → 3.32% (-0.18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$375M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$155M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$104M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$66.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$46.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$648M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$239M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$171M |
| 4 |
Temasek Holdings
Singapore
|
-$124M |
| 5 |
Morgan Stanley
New York
|
-$76.3M |
ONC Hedge Fund Activity: Q1 2025 in Review
267 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q1 2025, worth a combined $11.6B — up 44% from $8.07B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new ONC positions and 25 closed out — a net gain of 42 holders — while 83 added to existing stakes and 79 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $375M. The largest seller was HHLR Advisors, cutting an estimated $648M.
- 267 institutional investors held BeOne Medicines Ltd (ONC) as of Q1 2025, up from 228 in Q4 2024.
- Funds reported $11.6B of BeOne Medicines Ltd stock for Q1 2025, up 44% quarter-over-quarter.
- 67 funds opened new BeOne Medicines Ltd positions in Q1 2025 and 25 closed out, a net change of +42 holders.
- The largest BeOne Medicines Ltd buyer in Q1 2025 was Fidelity Investments, an estimated $375M added.
- The largest BeOne Medicines Ltd seller in Q1 2025 was HHLR Advisors, an estimated $648M sold.
Based on aggregated 13F filings for Q1 2025.